Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity.

2.50
Hdl Handle:
http://hdl.handle.net/10029/621139
Title:
Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity.
Authors:
Jansen, Marleen E; Rigter, T; Rodenburg, W; Fleur, T M C; Houwink, E J F; Weda, M; Cornel, Martina C
Abstract:
Advances from pharmacogenetics (PGx) have not been implemented into health care to the expected extent. One gap that will be addressed in this study is a lack of reporting on clinical validity and clinical utility of PGx-tests. A systematic review of current reporting in scientific literature was conducted on publications addressing PGx in the context of statins and muscle toxicity. Eighty-nine publications were included and information was selected on reported measures of effect, arguments, and accompanying conclusions. Most authors report associations to quantify the relationship between a genetic variation an outcome, such as adverse drug responses. Conclusions on the implementation of a PGx-test are generally based on these associations, without explicit mention of other measures relevant to evaluate the test's clinical validity and clinical utility. To gain insight in the clinical impact and select useful tests, additional outcomes are needed to estimate the clinical validity and utility, such as cost-effectiveness.
Citation:
Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity. 2017, 8:555 Front Pharmacol
Journal:
Front Pharmacol 2017, 8:555
Issue Date:
2017
URI:
http://hdl.handle.net/10029/621139
DOI:
10.3389/fphar.2017.00555
PubMed ID:
28878673
Type:
Article
Language:
en
ISSN:
1663-9812
Appears in Collections:
Miscellaneous

Full metadata record

DC FieldValue Language
dc.contributor.authorJansen, Marleen Een
dc.contributor.authorRigter, Ten
dc.contributor.authorRodenburg, Wen
dc.contributor.authorFleur, T M Cen
dc.contributor.authorHouwink, E J Fen
dc.contributor.authorWeda, Men
dc.contributor.authorCornel, Martina Cen
dc.date.accessioned2018-01-10T08:38:48Z-
dc.date.available2018-01-10T08:38:48Z-
dc.date.issued2017-
dc.identifier.citationReview of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity. 2017, 8:555 Front Pharmacolen
dc.identifier.issn1663-9812-
dc.identifier.pmid28878673-
dc.identifier.doi10.3389/fphar.2017.00555-
dc.identifier.urihttp://hdl.handle.net/10029/621139-
dc.description.abstractAdvances from pharmacogenetics (PGx) have not been implemented into health care to the expected extent. One gap that will be addressed in this study is a lack of reporting on clinical validity and clinical utility of PGx-tests. A systematic review of current reporting in scientific literature was conducted on publications addressing PGx in the context of statins and muscle toxicity. Eighty-nine publications were included and information was selected on reported measures of effect, arguments, and accompanying conclusions. Most authors report associations to quantify the relationship between a genetic variation an outcome, such as adverse drug responses. Conclusions on the implementation of a PGx-test are generally based on these associations, without explicit mention of other measures relevant to evaluate the test's clinical validity and clinical utility. To gain insight in the clinical impact and select useful tests, additional outcomes are needed to estimate the clinical validity and utility, such as cost-effectiveness.en
dc.language.isoenen
dc.rightsArchived with thanks to Frontiers in pharmacologyen
dc.titleReview of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity.en
dc.typeArticleen
dc.identifier.journalFront Pharmacol 2017, 8:555en

Related articles on PubMed

All Items in WARP are protected by copyright, with all rights reserved, unless otherwise indicated.